By Landon Gray
Originally published in our sister publication, Gastroenterology & Endoscopy News
Phathom announced the FDA approval of vonoprazan tablets, amoxicillin capsules, clarithromycin tablets (Voquezna Triple PAK, Phathom) and vonoprazan tablets, amoxicillin capsules (Voquezna Dual PAK, Phathom) for treatment of Helicobacter pylori infection in adults.
The approval of vonoprazan—a potassium-competitive acid blocker (PCAB)—marks the first time in 30 years that a novel